Rachel Abbott
Chief Executive Officer Pan Cancer T
Rachel Abbott joined Pan Cancer T in January 2023 as Chief Scientific Officer, bringing a wealth of scientific and industrial expertise in TCR-T cell therapies. She stepped up to become CEO in May 2023. Rachel began her biotech career in 2014 at Adaptimmune, where she oversaw the discovery of novel TCRs through T cell cloning, pipeline testing of affinity-enhanced TCRs, and large-scale T cell manufacturing for preclinical packages. She also led the pipeline development of a T cell therapy directed to PRAME and managed pre-IND safety and efficacy data packages for two next-generation NY-ESO targeting T cell products in partnership with GSK. Before joining Pan Cancer T, Rachel served for two years as Senior Director, Head of TCR Pipeline and Dark Antigen Research at Enara Bio. She holds a DPhil and an MBiochem in Molecular and Cellular Biochemistry from the University of Oxford and was a Research Fellow at the University of Birmingham for seven years.
Seminars
- Introducing a first-in-class TCR engineered therapy against a novel target expressed in over 90 percent of triple negative breast cancer and melanoma patients
- Demonstrating how built in co-stimulatory domains within the TCR can enhance T-cell durability while maintaining a compact engineering payload relevant for future in vivo delivery
- Translating promising preclinical data into a cost-effective and scalable clinical manufacturing strategy to unlock cell therapy for hard-to-treat solid tumors
